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Highlights 
 
●  Typhoid fever (TF) is a systemic illness and disseminated intravascular coagulation may 
occur  
● This study includes 2 patients groups, blood culture-positive and PCR-positive patients 
● The coagulation system is strongly activated in most TF patients involving all 3 major 
pathways  
● A fifth of TF patients had marked thrombocytopenia, a proposed marker for severity of 
disease 
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Abstract  
 
Objectives: Typhoid fever caused by Salmonella Typhi remains a major burden worldwide. 
Gastrointestinal bleeding can be seen in up to 10 percent of patients and may be fatal. The 
coagulopathy, which may be the driver of this severe complication in patients with typhoid 
fever, however is ill defined. The aim of this study was to evaluate the activation of 
coagulation, anticoagulation, and fibrinolysis in patients with acute typhoid fever.  
Methods. Parameters of coagulation and fibrinolysis were measured in 28 hospitalized 
patients with culture-confirmed or PCR-confirmed typhoid fever and compared to 38 age- 
and sex-matched healthy volunteers.  
Results. Patients demonstrated activation of the coagulation system, as reflected by elevated 
in vitro thrombin generation and high plasma levels of fibrinogen, D-dimer and prothrombin 
fragment F1+2 in concert with consumption of coagulation factors resulting in a prolonged 
prothrombin-time and activated-partial-thromboplastin-time. Concurrently, the anticoagulant 
proteins, protein C and antithrombin, were significantly lower in comparison to healthy 
controls. Patients also demonstrated evidence of activation and inhibition of fibrinolysis and a 
marked activation of endothelial cells. The extent of coagulation activation was associated 
with the course of the disease, repeated testing during convalescence showed a return toward 
normal values. 
Conclusions. Activation of coagulation is an important clinical feature of typhoid fever and is 
associated with severity of disease. 
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Introduction 
 
Typhoid fever is a systemic disease caused by the Gram-negative bacteria Salmonella (S.) 
enterica serovar Typhi that constitutes a global problem with an estimated 21 million cases 
annually resulting in over 220,000 deaths (1-3). Patients with typhoid fever usually present 
with protracted high grade fever, and characteristically a normal to low white blood cell and 
platelet count (4). Gastrointestinal bleeding has been previously described as the most 
common complication in typhoid fever, occurring in up to 10 percent of patients (5). In the 
majority of cases, the bleeding is minimal and resolves without the need for intervention (6). 
In a small percentage of cases however bleeding is significant and can become fatal (7), 
however more recent data is lacking on the actual incidence on intestinal hemorrhage and the 
case fatality rate.  
 
Our understanding of the underlying mechanisms responsible for gastrointestinal bleeding 
and the role of the coagulation system and fibrinolysis in the pathogenesis of typhoid fever is 
limited. The extent of disseminated intravascular coagulation (DIC), which is characterized 
by widespread activation of coagulation resulting in intravascular formation of fibrin (8), has 
been proposed as a marker of disease severity in typhoid fever (9, 10). Conversely, others 
have reported that DIC is mostly a subclinical event and found bleeding complications in 
typhoid fever to be uncommon. Notably, in terms of blood coagulation, it has been suggested 
that circulating bacteria and endotoxin do not play an important role in typhoid fever 
pathogenesis (11). Interestingly, preclinical work has recently identified a new virulence 
factor of S. Typhi - called Typhi chimaeric A2B5 typhoid toxin or exotoxin - which is thought 
to contribute to the acute symptomatology in patients with typhoid fever by activation of, 
among other factors, vascular endothelial cells (12). 
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The aim of this study was to obtain new insights into the pathogenesis of typhoid fever by 
defining the involvement of the coagulation, endothelium and fibrinolytic systems in patients 
hospitalized with this infection. In addition to the endothelium, we focused on the three major 
pathways – procoagulant, anticoagulant, and fibrinolytic – that together determine the overall 
balance of clot formation and resolution. Furthermore, we investigated whether the extent of 
coagulation activation correlated with a positive blood culture and the presence of disease 
complications.  
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Materials and methods  
 
Ethical statement 
The study protocol was approved by the National Research Ethics Committee (NREC) of 
Bangladesh (BMRC/NREC/2010-2013/1543) and the Oxford Tropical Research Ethics 
committee (OXTREC-reference 25-11). 
 
Patients and study design  
In order to include patients hospitalized with typhoid fever, we performed a prospective all-
cause fever study from January 2012 through June 2012 in Chittagong Medical College 
Hospital in Chittagong, Bangladesh as previously described (13-15). Consecutive patients 
(≥16 years of age) who were admitted with an acute febrile illness (documented fever ≥38°C 
axillary, up to 48 hours after admission, history of fever less than 2 weeks) were recruited 
after giving informed written consent. History and physical examination findings were 
recorded; baseline complete blood counts, renal and liver functions tests were analyzed. 
Blood serum, urine, and feces samples were obtained at admission and day 10 post fever 
onset or at hospital discharge and stored at -20°C. Plasma was prepared from blood collected 
in EDTA and citrate tubes (BD vacutainer®) and stored immediately at -70°C pending 
analysis. Blood cultures at admission were performed by inoculating 8-10 mL of blood into 
BacT/ALERT FA blood culture bottles and incubated in the BacT/ALERT automated system 
(Biomerieux) for 5 days. Positive bottles were processed by standard microbiological 
methods. If the Gram-stain showed Gram-negative bacilli, blood culture fluid was tested for 
S. Typhi and was identified using API biochemical testing (Biomerieux) and specific antisera 
(BioRad). Bacterial isolates were stored on agar slopes and couriered to Oxford University 
Clinical Research Unit (OUCRU) in Ho Chi Minh City, Vietnam for confirmation of 
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identification. Real-time PCR was performed on stored blood, urine and feces samples 
targeting STY0201 (Putative fimbrial adhesion in S. Typhi CT18) or SSPA2308 (hypothetical 
protein in SPA AKU-12601) as described (16).  
A diagnosis of typhoid fever was confirmed if S. Typhi was isolated from the blood 
culture and/or the real-time PCR indicated the presence of S. Typhi targets in blood, urine or 
feces. Complicated typhoid fever was defined if one or more of the following were present: 
gastrointestinal bleeding (the presence of visible blood in the stool); intestinal perforation; 
encephalopathy (delirium, obtundation or coma); hemodynamic shock; renal impairment 
(creatinine level >2.0 mg/dL); hepatitis (as indicated by AST or ALT level ≥1000 U/L); 
pneumonia (respiratory symptoms with abnormal chest X-ray shadowing) or pleural effusion; 
the presence of a focal septic complication; severe anemia (hematocrit ≤20%), the need for a 
blood transfusion and death in hospital (5, 7). Thrombocytopenia was defined as a platelet 
count of <100 x 10
9
/L.  
38 Bangladeshi volunteers who were known to have no illness that could affect 
hemostasis and were not currently receiving any medication served as healthy controls.  
 
Assays 
Stored ETDA and citrated plasma were stored at -80
0
C except when transferred on dry ice to 
the Academic Medical Center, Amsterdam for the coagulation related assays. Prothrombin 
time (PT), activated partial thromboplastin time (APTT), antithrombin (AT) and D-dimer 
were assayed on an automated blood coagulation analyzer (BCS® XP, Siemens). Fibrinogen 
levels were derived from the change in optical signal in the PT. Prothrombin fragment F1+2 
(F1+2) (Enzygnost®, Siemens), plasmin-alpha2-antiplasmin complexes (PAPc; DRG 
Diagnostics), soluble form of the urokinase-type plasminogen activator receptor (suPAR; 
suPARgnostics®, Virogates), endothelial cell specific molecule (ESM)-1/Endocan 
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(Lunginnov), plasminogen activator inhibitor (PAI)-1 and tissue-type plasminogen activator 
(tPA) (Biomed) were determined by enzyme-linked immunosorbent assays (ELISA) (17, 18). 
Von Willebrand factor (VWF, percentages) and total protein S levels were determined with 
in-house ELISAs (using antibodies from Dako) (19). Free protein S was measured by 
precipitating the C4b-binding protein-bound fraction with polyethylene glycol 8000, then 
measuring the concentration of free protein S in the supernatant. Protein C was assayed by 
kinetic assay (Coamatic®, Chromogenix™). Of note, AT and tPA were only measured in the 
blood culture-positive sub-set of patients due to limited volumes of plasma collected on day 
of enrolment. In vitro thrombin generation with 5 pM tissue factor and associated measures 
(lag time, peak, time-to-peak, area-under-the-curve (or endogenous thrombin potential (ETP), 
and velocity index) were assayed with the Calibrated Automated Thrombogram® 
(Fluoroskan Ascent, ThermoLab systems) and Thrombinoscope® software (Thrombinoscope 
BV) (18, 20). Resistance to activated protein C (APC) was determined by testing the effect of 
APC (Enzyme Research Laboratories) on the endogenous thrombin potential (ETP) with the 
CAT assay. APC-sensitivity of each plasma sample was determined in both the presence and 
absence of ~4 nM APC. APC concentrations used were adjusted to maintain a residual 
thrombin generation activity of ~10% in normal pooled plasma. The normalized ratio 
(APCsr) was determined by dividing the APCsr of an individual by the APCsr of the pooled 
plasma (a ratio >1.6 reflects an APC resistant phenotype). DIC scores were calculated using 
the International Society on Thrombosis and Hemostasis (ISTH) standardized method (21). 
 
Statistical analysis 
A primary analysis was performed in which results for control subjects and patients with 
typhoid fever were compared. Subgroup analysis was performed to compare results from 
patients with blood culture-positive for S. Typhi species with those from culture-negative but 
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PCR positive patients and to compare results from patients with complicated disease with 
those from patients with uncomplicated disease. 
Data on patient's characteristics and laboratory results were compared between different 
groups using student's t-test or Mann-Whitney U for continuous variables, and the χ2 test or 
Fisher's exact test for categorical variables as appropriate. Correlations were calculated using 
the Spearman rho test. All analyses were performed using Graphpad prism, version 6 for Mac 
(Graphpad Software).  
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Results 
 
Patients 
A total of 144 consecutive patients with fever admitted to the hospital were enrolled in this 
study, of which 28 had confirmed typhoid fever (19.4%). Of these confirmed typhoid fever 
cases, 11 (39%) were diagnosed by isolation of S. Typhi from blood, and 17 (61%) by 
positive S. Typhi PCR in blood (15), urine (2) and/or feces (1). Thirty-eight healthy local 
volunteers served as controls. Baseline clinical features are shown in Table 1. Patients with 
typhoid fever had significantly lower median platelet counts than the control group (P<.0001; 
Figure 1A). There was one death (3.7%) due to septic shock in the group of patients who 
were S. Typhi culture-negative but S. Typhi blood PCR-positive. 
 
Activation of coagulation in typhoid fever  
In patients with typhoid fever, coagulation was significantly enhanced as reflected by 
elevated plasma concentrations of F1+2 and D-dimer when compared to healthy controls 
(P<.0001 for both comparisons; Figure 1B-C). Fibrinogen levels were strongly elevated in 
patients versus controls (P<.0001; Figure 1D). In addition, both PT and APTT were 
prolonged in patients compared to controls, suggesting an increased consumption of clotting 
factors (P<.01-.0001; Figure 1E-F). The observed differences in F1+2, D-dimer, fibrinogen, 
PT and APTT were preserved in subgroup analyses, in which culture-negative but PCR-
positive and culture-positive groups were compared separately against the controls (Figure 1). 
To further investigate the functionality of the detected coagulation activation, we analyzed 
the coagulation potential of plasma induced by tissue factor by calibrated automated 
thrombinography (CAT, Figure 2A) (18, 20). In typhoid fever patients, the lag-time was 
significantly prolonged in comparison to the controls, which is in line with the observed 
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prolonged PTs (P<.0001; Figure 2B). The peak thrombin (Figure 2C) and velocity index 
(data not shown) had higher median levels in patients which could be a direct result of 
affected anticoagulant pathways, since antithrombin is an important determinant of CAT 
(20). The area-under-the-curve (or ETP) did not differ between typhoid and controls 
suggesting that despite delayed coagulation initiation, the amount of thrombin and thus clots 
that can be formed during typhoid fever is similar between groups (Figure 2D). In the 
subgroup analyses, culture-negative and PCR-positive patients had higher peak thrombin 
levels and higher median ETP compared to controls, implying that this subgroup have a 
greater ability to generate thrombin (P<.05; Figure 2).  
 
Activation of the vascular endothelium 
During acute inflammation, the endothelium becomes activated, which contributes to the 
attraction of leukocytes and formation of a thrombus (22, 23). Recent preclinical work has 
shown that S. Typhi exotoxin interacts with podocalyxin-like protein-1 which localizes to the 
apical side of epithelial cells and is expressed in vascular endothelial cells (12). We found 
strong endothelium activation in typhoid fever patients when compared to controls as 
reflected by increased levels of VWF, a large multimer secreted by endothelial cells 
following stimulation by among others endotoxin, cytokines or thrombin (P<.0001; Figure 
3A) (18, 24). VWF plays a key role in platelet adhesion and aggregation and observed low 
platelet counts in typhoid fever patients strongly correlated with VWF concentrations (r=-
0.41, P<.001; Figure 3B). Further evidence of activation of vascular endothelium was 
provided by measurements of endocan, a newly described soluble proteoglycan expressed by 
endothelial cells and which expression relates with severity of illness in patients with sepsis 
(25). Endocan was elevated in patients when compared to controls; subgroup analyses 
showed that endocan levels in the culture-positive group were higher than in the culture-
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negative PCR-positive patients (P<.0001; Figure 3C). 
 
Downregulation of anticoagulant pathways 
Coagulation activation in patients with typhoid fever was paralleled with a depression of 
anticoagulation pathways: AT and protein C concentrations were decreased and APC-
sensitivity ratios were increased in patients compared to healthy controls (P<.05, P<.0001 
and P<.01 respectively; Figure 4A-C). Total (and free, data not shown) protein S levels were 
not different in patients compared to controls (Figure 4D).  
 
Activation and inhibition of fibrinolysis 
Patients with typhoid fever demonstrated evidence of activation and inhibition of fibrinolysis, 
as reflected by elevated plasma levels of tPA and PAI-1 (P<.05, and P < .01 respectively; 
Figure 5A-B). In addition, patients showed strongly increased PAPc when compared to 
healthy subjects (P<.001; Figure 5C). Levels of suPAR, an important soluble mediator of 
fibrinolysis that is proposed as a potential prognostic biomarker for sepsis (26, 27), were 
significantly higher in patients compared to controls (P<.0001; Figure 5D). To assess 
coagulation–fibrinolysis (im)balance we assessed DIC scores which were strongly increased 
in patients compared to controls, with 5 patients (18%) having a DIC score ≥5. These 
differences were preserved in the subgroup analysis, in which culture-negative and culture-
positives were compared separately with controls (P<.0001; Figure 5E).  
 
Association between coagulation abnormalities and severity of disease 
Having characterized the spectrum of coagulation activation in typhoid fever, we next sought 
to examine associations between the coagulation profile and clinical severity. Eleven (39%) 
patients were classified as having complicated typhoid fever. Specific complications were: 
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pneumonia (3); encephalopathy (2); gastrointestinal bleeding (1); severe anemia requiring 
blood transfusion (1); acute hepatitis (1); hepatic abscess (1); septic arthritis (1); and renal 
failure, cardiopulmonary arrest and death (1). Having a positive blood culture did not result in 
a higher risk of developing a complication in this study, only 2 out 8 patients with a positive 
blood culture developed a complication. Fibrinogen levels were significantly elevated in 
patients with complicated typhoid fever when compared to patients with uncomplicated 
typhoid fever (median (IQR); 7.4 (5-7) vs 4.7 (4-5), P<.01). Other measured abnormalities in 
coagulation, anti-coagulation and fibrinolysis or endothelium activation were not associated 
with the presence of complications (data not shown). The extent of coagulation activation 
correlated with the stage of the disease; most measured markers showed complete (APTT, 
endocan, protein C; P<.01-.05; Figure 6 (mean with 95% CI) or near complete normalization 
(F1+2, D-dimer, fibrinogen, PT, PAI-1 and suPAR; data not shown) in patients from whom 
follow-up samples were available at discharge. Plasma levels of VWF and PAPc were not yet 
normalized at time of discharge (data not shown). Furthermore, in patients the platelet count 
– but not white blood cell count - negatively correlated with almost all coagulation and 
fibrinolysis markers (P<.05; except for fibrinogen, P=.06) and positively correlated with the 
natural anticoagulant protein C (P<.0001).  
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Discussion 
 
Different forms of bleeding have been described in typhoid fever, either self-limiting local 
hemorrhage in the gastrointestinal tract due to inflammation or generalized bleeding as a 
result of imbalance in the activation of coagulation (28). In the present study, we demonstrate 
that the coagulation system is markedly activated in almost all patients involving all three 
major pathways: procoagulant, anticoagulant, and fibrinolytic. These results shed light on the 
potential mechanisms responsible for the different forms of bleeding observed in these 
patients.  
 Our data point to an overall prothrombotic state in typhoid fever. Patients 
demonstrated increased plasma prothrombin fragments as well as fibrin degradation products 
and lower protein C and AT concentrations than healthy controls. The ability to generate 
thrombin in vitro was partially delayed in patients confirming the prolonged PT, but patients 
were capable of generating higher amounts of thrombin, which is most likely the result of the 
affected anticoagulation pathways, as these are important determinants of in vitro thrombin 
generation (20). Moreover, DIC scores, which provide insight into the coagulation–
fibrinolysis (im)balance (8), were markedly elevated in the majority of typhoid fever patients. 
Furthermore, in this study we were able to collect samples from patients on day of admission 
and on day of discharge, which gave us a further insight into the course of disease. The extent 
of coagulation activation correlated with the course of disease, most measured markers 
showed complete or near normalization during convalescence. However, samples were only 
collected acutely and at time of hospital discharge - there are multiple other factors apart 
from disease progression, which may account for these differences such as use of antibiotics. 
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Fibrinolysis was grossly activated in our cohort of patients as shown by increased tPA 
and PAPc levels. In addition, our data on reduced expression of anticoagulant mechanisms 
are consistent with previous investigations reporting low circulating levels of protein C and 
AT in typhoid fever (28, 29), which could, in part, contribute to the development of DIC. Of 
note, protein C becomes activated by the thrombin-thrombomodulin complex. In a previous 
study, an increase in soluble thrombomodulin was found in patients with typhoid fever (30).  
One would hypothesise that increased levels of soluble thrombomodulin would lead to 
elevated levels of thrombin-trombomodulin complexes and enhanced consumption of protein 
C. In addition, we found an APC resistant phenotype. APC is an anticoagulant as it 
inactivates factors Va and VIIIa. Reduced sensitivity for APC, caused by for instance a factor 
V Leiden mutation, is a well-established risk factor for the development of venous 
thrombosis (31). We now demonstrate that patients with typhoid fever patients have 
decreased plasma protein C concentrations together with an APC-resistant phenotype.  
 Our study design uniquely enabled us to compare markers of coagulation and 
fibrinolysis in blood culture-positive and culture-negative/PCR-positive patients in the same 
population in order to generate future hypotheses. Therefore no adjustments were made for 
multiple comparisons. We demonstrate that virtually all measured markers are significantly 
affected by typhoid fever and there was a trend to more pronounced activation of coagulation, 
fibrinolysis and endothelium with concurrent impaired of anticoagulant pathways in the 
blood culture-positive group when compared to the culture-negative/PCR-positive patients. 
The presence of bacteria in the systemic compartment could contribute to this phenomenon 
due to increased shedding of endotoxin and/or the recently discovered S. Typhi exotoxin (12). 
Endotoxin has previously been suggested to be the prime mediator of the hematologic 
changes observed in typhoid patients (11, 32) and indeed is a known potent inducer of 
coagulation (22, 24). Its role as a virulence factor in typhoid fever however is debatable as S. 
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Typhi’s Vi capsule can prevent endotoxin recognition by the host (2, 33). In addition, 
endotoxins could not be detected in typhoid fever patients with severe DIC (11). The 
exotoxin of S. Typhi can, however, interact with the vascular endothelium (12) and perhaps 
contributes to the signs and symptoms of typhoid fever. We now observe that markers of 
endothelial activation, most notably VWF and endocan, are sharply increased in the blood 
culture-positive group when compared to the culture-negative/PCR-positive group. However, 
the significance of the activation of coagulation, fibrinolysis, and concurrent downregulation 
of the anticoagulation, is limited by the lack of a non-typhoid febrile control group, which 
calls into question whether this is a typhoid-specific phenomenon. 
 Acute infection can result in systemic activation of coagulation (22, 24). One could 
postulate that in typhoid fever the activation of coagulation and deposition of fibrin as a 
consequence of inflammation can be considered instrumental in containing inflammatory 
activity. Immunologic functions of thrombi are critically dependent on platelets. (23). In our 
study, 18% of typhoid fever patients had marked thrombocytopenia and most measured 
markers for coagulation negatively correlated with platelet count. The mechanism of 
thrombocytopenia in typhoid fever remains ill defined. It has been postulated that defects in 
the production of platelets are caused by a direct toxic effect of Salmonella on the bone 
marrow (34), while others have suggested non-immune platelet destruction to be an effect of 
DIC (23, 35). More recent insights indicate that the abundant presence of hemophagocytes 
during Salmonella infections, which are important for intracellular replication and thus 
maintenance of chronic infection, could in part explain the low platelet – as well as leukocyte 
– counts commonly seen in typhoid fever (36).  
 In summary, our data show that acute typhoid fever is characterized by activation of 
coagulation and endothelium, activation and inhibition of fibrinolysis and concurrent 
impairment of anticoagulant mechanisms. The clinical importance of our findings is 
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underscored by the association between the observed disturbances in the coagulation cascade 
and the course of disease. Repeated testing during convalescence showed a return toward 
normal values. 
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Figure legends 
 
Figure 1.  Activation of coagulation 
Coagulation factors (Platelets, A; Prothrombin fragment 1+2, B; D-dimer, C; Fibrinogen, D;  
Prothrombin time, E; Activated partial thromboplastin time, F)  in patients with typhoid fever 
(empty squares) who were culture positive (black triangles) or culture negative (empty 
triangles) for S. Typhi and in healthy Bangladeshi control subjects (empty circles). Data are 
expressed as dot plots with medians.  
F1+2: prothrombin fragment 1+2; PT: prothrombin time; APTT: activated partial 
thromboplastin time.  
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Figure 2.  In vitro thrombin generation 
In vitro thrombin generation (thrombin generation assay, A; Lag time, B; Peak thrombin, C; 
Endogenous thrombin potential, D) assessed in typhoid fever patients (empty squares) who 
were culture positive (black triangles) or culture negative (empty triangles) for S. Typhi and 
of healthy Bangladeshi control subjects (empty circles). Data are expressed as dot plots with 
medians.  
ETP: endogenous thrombin potential. 
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Figure 3. Activation of vascular endothelium 
Activation of the endothelium (von Willebrand factor, A; Endothelial cell specific molecule-
1, C) in patients with typhoid fever (empty squares) who were culture positive (black 
triangles) or culture negative (empty triangles) for S. Typhi and in healthy Bangladeshi 
control subjects (empty circles). Data are expressed as dot plots with medians. Correlation 
curve platelet count versus von Willebrand factor (B). P-value and Spearman Rho, linear 
regression analysis.  
VWF: von Willebrand factor; ESM-1/Endocan: endothelial cell specific molecule-1. 
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Figure 4.  Anticoagulation 
Anticoagulant factors (Antithrombin, A; Protein C, B; Activated protein C sensitivity ratio, 
C; Total protein S, D) in patients with typhoid fever (empty squares) who were culture 
positive (black triangles) or culture negative (empty triangles) for S. Typhi and in healthy 
Bangladeshi control subjects (empty circles). Data are expressed as dot plots with medians. 
AT: antithrombin; APC: activated protein C.  
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Figure 5. Activation and inhibition of fibrinolysis 
Activation and inhibition (Tissue-type plasminogen activator, A; Plasminogen activator 
inhibitor type, B; Plasmin-alpha2-antiplasmin complexes, C; Soluble form of the urokinase-
type plasminogen activator receptor, D; Disseminated intravascular coagulation, E) of 
fibrinolysis in patients with typhoid fever (empty squares) who were culture positive (black 
triangles) or culture negative (empty triangles) for S. Typhi and in healthy Bangladeshi 
control subjects (empty circles). Data are expressed as dot plots with medians.  Data are 
expressed as dot plots with medians.  
tPA: tissue-type plasminogen activator; PAI-1: plasminogen activator inhibitor type; PAPc: 
plasmin-alpha2-antiplasmin complexes; suPAR: soluble form of the urokinase-type 
plasminogen activator receptor; DIC: disseminated intravascular coagulation. 
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Figure 6.  Association between coagulation abnormalities and severity of disease 
The normalization of three parameters (Activated partial thromboplastin time, A; Endothelial 
cell specific molecule-1, B; Protein C, C) over time in typhoid fever patients (n=16 patients). 
The time points are day of enrollment, and day of discharge (mean with 95% CI). Dotted line 
represents reference values of healthy controls.   
APTT: activated partial thromboplasmin time; ESM-1/Endocan: endothelial cell specific 
molecule-1
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Table 1. Baseline information for 28 patients with typhoid fever, comparing culture-positive and culture-negative groups. 
 
All values are reported as median value mean (range) unless stated otherwise. NS: not significant; WBC: white blood cell count. 
a
 comparison between healthy controls and typhoid fever patients 
b
 comparison between culture negative/PCR+ and culture positive patients  
c 
Normal range, not measured in the control group 
 
    Patients with typhoid fever  
 
 
Characteristic 
 
Healthy 
controls 
(n=38) 
 
All 
(n=28) 
 
 
P value
a
 
 
Culture negative 
for S. Typhi 
(n=17) 
 
Culture positive 
for S. Typhi 
(n=11) 
 
 
P value
b
 
Age, years 33.5 (19-55) 28 (20-45) NS 31 (20-45) 25 (20-45) NS 
Male sex, no. (%) of patients 19 (50) 16 (57) NS 10 (59) 6 (55) NS 
Fever duration before admission, days 0 (0-1) 7 (1-15) <.0001 5 (1-15) 7 (4-14) NS 
Duration of admission, days 0 (0-0) 5 (0-12) <.0001 4 (0-10) 5 (0-12) NS 
Temperature (Celsius, axillary) 36.1 (33.8-37.4) 38.8 (38-40.1) <.0001 38.9 (38-39.9) 38.6 (38.3-40.1) NS 
Systolic blood pressure, mmHg 120 (106-169) 116 (85-159) .01 118 (90-140) 111 (85-195) NS 
Pulse, beats/min 72.5 (40-120) 104 (70-150) <.0001 96 (70-120) 110 (89-150) .04 
Blood urea nitrogen, mg/dL 6-20
c
 12.5 (9.3-76) - 12.8 (10-76) 12 (9.3-15) NS 
Serum creatinine level, mg/dL 0.1-0.5
c
 0.9 (0.6-2.2) - 0.9 (0.7-2.2) 0.9 (0.6-1.3) NS 
Aspartate aminotransferase level, U/L <40
c
 40 (13-1430) - 31 (13-1430) 80 (37-450) NS 
Alanine aminotransferase level, U/L <45
c
 49 (15-1199) - 33 (15-1199) 60 (24-220) NS 
Hemoglobin level, g/dl 13.3 (8.4-15.5) 12.1 (3.5-14.5) .002 12 (3.5-14.4) 12.4 (7.5-14.5) NS 
WBC count, x10
9
 cells/L 7.5 (4.5-10) 9 (1.5-29) NS 10.8 (1.5-29) 6.2 (4-14) .03 
Neutrophil percentage 57 (42.9-76) 76.5 (3-92.1) .0001 72 (3-92.1) 78 (62-90) NS 
Monocyte percentage 3 (2-9.3) 2 (0-7) NS 2 (0-7) 2 (1-4) NS 
Lymphocyte percentage 35.5 (20-50) 19 (1-36) .0001 1 (1-36) 20 (8-35) NS 
Death, no. (%) of patients 0 (0) 1 (3.7) - 1 (6.3) 0 (0) NS 
